Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, lpr, and Bcl-2-transgenic mice
- PMID: 7604887
- PMCID: PMC1869886
Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, lpr, and Bcl-2-transgenic mice
Abstract
This report examines the mechanisms involved in the down-regulation of the immune response in acute viral infection and documents the presence of apoptotic lymphocytes in situ in the spleens of mice during the resolution of the immune response to acute lymphocytic choriomeningitis virus infection. Apoptotic cells were detected by an in situ nucleotidyl transferase assay. Both T and B lymphocytes were shown to be dying in vivo, the latter in clusters. A biphasic occurrence of apoptosis during the course of the acute infection was observed, with elevated levels occurring at day 3 after infection and a second more pronounced peak at day 11 after infection, coincident with the decline of the cytotoxic T lymphocyte response and with the decrease in total splenic leukocyte number. Apoptosis in vivo was detected in lpr mice, suggesting that Fas expression is not imperative for lymphocyte apoptosis in the context of an acute viral infection. Apoptosis in situ and the decline of the T lymphocyte response to acute lymphocytic choriomeningitis virus infection was unaffected by the enforced lymphocyte-directed expression of Bcl-2, a protein that blocks growth factor deprivation-induced apoptosis of lymphocytes in vitro. These results argue that the silencing of the T cell response to acute infection may not be a result simply of growth factor deprivation. The susceptibility of activated T cells to apoptotic death, which has previously been associated with virus-induced immune deficiency, may therefore also explain the en masse elimination of the expanded lymphocyte pool subsequent to an acute viral infection.
Similar articles
-
T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions.J Virol. 1996 Nov;70(11):8199-203. doi: 10.1128/JVI.70.11.8199-8203.1996. J Virol. 1996. PMID: 8892953 Free PMC article.
-
Homeostatic regulation of CD8+ T cells after antigen challenge in the absence of Fas (CD95).Eur J Immunol. 1996 Dec;26(12):2903-10. doi: 10.1002/eji.1830261215. Eur J Immunol. 1996. PMID: 8977284
-
Role of Bim in regulating CD8+ T-cell responses during chronic viral infection.J Virol. 2006 Sep;80(17):8627-38. doi: 10.1128/JVI.00855-06. J Virol. 2006. PMID: 16912311 Free PMC article.
-
Immune deficiency, immune silencing, and clonal exhaustion of T cell responses during viral infections.Curr Opin Microbiol. 1999 Aug;2(4):382-7. doi: 10.1016/s1369-5274(99)80067-8. Curr Opin Microbiol. 1999. PMID: 10458980 Review.
-
The power and the promise of restimulation-induced cell death in human immune diseases.Immunol Rev. 2010 Jul;236:68-82. doi: 10.1111/j.1600-065X.2010.00917.x. Immunol Rev. 2010. PMID: 20636809 Free PMC article. Review.
Cited by
-
Emergent group dynamics governed by regulatory cells produce a robust primary T cell response.Bull Math Biol. 2010 Apr;72(3):611-44. doi: 10.1007/s11538-009-9463-1. Epub 2009 Dec 16. Bull Math Biol. 2010. PMID: 20013355 Free PMC article.
-
Role of tumor necrosis factor receptors in regulating CD8 T-cell responses during acute lymphocytic choriomeningitis virus infection.J Virol. 2005 Jan;79(1):202-13. doi: 10.1128/JVI.79.1.202-213.2005. J Virol. 2005. PMID: 15596816 Free PMC article.
-
Antigen-mediated T cell expansion regulated by parallel pathways of death.Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17463-8. doi: 10.1073/pnas.0808043105. Epub 2008 Nov 3. Proc Natl Acad Sci U S A. 2008. PMID: 18981423 Free PMC article.
-
T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions.J Virol. 1996 Nov;70(11):8199-203. doi: 10.1128/JVI.70.11.8199-8203.1996. J Virol. 1996. PMID: 8892953 Free PMC article.
-
Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.Sci Transl Med. 2012 Jan 18;4(117):117ra7. doi: 10.1126/scitranslmed.3003008. Sci Transl Med. 2012. PMID: 22261031 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous